NCT06498973View on ClinicalTrials.gov

Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant

PHASE1RecruitingINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

January 28, 2025

Primary Completion Date

April 25, 2027

Study Completion Date

April 25, 2027

Conditions
Acute Myeloid LeukemiaMyelodysplastic Syndrome
Interventions
DRUG

Azacitidine

Given IV

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow aspiration and biopsy

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow aspiration and biopsy

OTHER

Questionnaire Administration

Ancillary studies

BIOLOGICAL

Tagraxofusp-erzs

Given IV

Trial Locations (1)

91010

RECRUITING

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER